Greg Bailey, Co-founder and Executive Chairman at Juvenescence, joins Phil Newman for a chat at Investing in the Age of Longevity 2024. Highlighting 2025 as an inflection point for both Juvenescence and the industry as a whole, Greg outlines some of his company's assets as well as the progress made with getting therapeutics into clinical trials. He also looks back at the longevity investment marketplace, and why now is a golden opportunity for investors to get onboard. Summarising Juvenescence's approach as a mix of business models, Greg shares his view on the potential provided by the consumer marketplace. 

For more investment and economics analysis plus inspiration please visit our website masterinvestor.co.uk.